Spotlight On... Mouse study offers evidence of Huntington's drug safety; Alzheimer's linked to certain amyloid peptides; Language dementia tied to toxic amyloid clusters in the brain

Researchers at Emory University say they have run mouse studies that help to prove that eliminating a gene which triggers Huntington's disease--the focus of drugs in the clinic--shouldn't have any unexpected health consequences in adults. That huntingtin gene, which triggers brain cell death, is vitally necessary for embryonic development. But this animal study provides some added evidence that eliminating the gene in adults won't spur side effects. That's a theory, though, that will have to be tested carefully in human trials. Release

> Investigators at Lund University say that the accumulation of amyloid beta in the brain is associated with elevated levels of certain amyloid peptides in cerebrospinal fluid, making them candidates for the disease even if they do not have a hereditary risk. Release

> A rare type of language dementia, primary progressive aphasia, has been linked with the accumulation of toxic amyloid clusters on the left side of the brain, where language is processed. Release

 

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.